Thomas J. Schall net worth and biography

Thomas Schall Biography and Net Worth

Director of Immuneering

Dr. Schall has served on our Board of Directors since March 2024. Dr. Schall founded ChemoCentryx, Inc. and served as its President, Chief Executive Officer and Chairman for 25 years until its acquisition by Amgen in 2022. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute (“DNAX”), a division of Schering-Plough Corporation. Prior to DNAX, he was a scientist with Genentech, Inc. Dr. Schall participated in early discoveries of chemokine system function and activities, and his laboratories have been responsible for the discovery or co-discovery of numerous known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

What is Thomas J. Schall's net worth?: The estimated net worth of Thomas J. Schall is at least $377.49 thousand as of January 15th, 2026. Dr. Schall owns 74,530 shares of Immuneering stock worth more than $377,494 as of May 6th. This net worth estimate does not reflect any other investments that Dr. Schall may own. Learn More about Thomas J. Schall's net worth.
How do I contact Thomas J. Schall?: The corporate mailing address for Dr. Schall and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Thomas J. Schall's contact information.
Has Thomas J. Schall been buying or selling shares of Immuneering?: Thomas J. Schall has not been actively trading shares of Immuneering in the last ninety days. Most recently, on Thursday, January 15th, Thomas J. Schall bought 21,645 shares of Immuneering stock. The stock was acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the completion of the transaction, the director now directly owns 74,530 shares of the company's stock, valued at $348,055.10. Learn More on Thomas J. Schall's trading history.
Who are Immuneering's active insiders?: Immuneering's insider roster includes Peter Feinberg (Director), Brett Hall (Chief Scientific Officer), Diana Hausman (Director), Thomas Schall (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.
Are insiders buying or selling shares of Immuneering?: In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.
Information on this page was last updated on 1/16/2026.

Thomas J. Schall Insider Trading History at Immuneering

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/15/2026	Buy	21,645	$4.67	$101,082.15	74,530
6/27/2025	Buy	9,500	$3.66	$34,770.00	52,885
6/17/2025	Buy	40,485	$2.21	$89,471.85	43,385

Thomas J. Schall Buying and Selling Activity at Immuneering

Immuneering Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Today's Range

Now: $5.15

$5.06

$5.40

50 Day Range

MA: $5.32

$4.78

$6.13

2 Week Range

Now: $5.15

$1.10

$10.08

Volume

615,911 shs

Average Volume

1,387,192 shs

Market Capitalization

$332.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37